<DOC>
	<DOCNO>NCT00664716</DOCNO>
	<brief_summary>Safety efficacy BG9924 RA participant inadequate response disease-modifying anti-rheumatic drug ( DMARD ) therapy .</brief_summary>
	<brief_title>Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis ( RA ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Diagnosis RA ( functional class I III ) Stable dose MTX Inadequate response least one conventional DMARD therapy Key Serious local infection systemic infection History ( Hx ) recurrent infection require oral parenteral antiinfective treatment Hx tuberculosis ( TB ) positive purify protein derivative ( PPD ) test screen period Clinical significant lab test screen Positive Hep C Hep B screen NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>DMARD inadequate response</keyword>
	<keyword>Methotrexate</keyword>
</DOC>